Journal of Clinical Psychopharmacology最新文献

{"title":"Sertraline-Associated Pathologic Laughter in a Patient With Major Depressive Disorder: A Very Rare Side Effect of a Commonly Used Drug.","authors":"Okan Ekinci","doi":"10.1097/JCP.0000000000002059","DOIUrl":"10.1097/JCP.0000000000002059","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"513-515"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144821574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"All Patients With Catatonia Deserve Proper Diagnosis, Theragnosis, and Prognosis.","authors":"João Gama Marques","doi":"10.1097/JCP.0000000000002038","DOIUrl":"10.1097/JCP.0000000000002038","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"531-532"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144284469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"I Am Depressed\": The Many Meanings That May Underlie Variability in Response to Antidepressants.","authors":"Richard I Shader, Antonio E Nardi, Richard Balon, Anthony J Rothschild, Larissa Junkes","doi":"10.1097/JCP.0000000000002053","DOIUrl":"10.1097/JCP.0000000000002053","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"418-420"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144846585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fact Versus Fear: Antidepressants in Children and Adolescents.","authors":"Jeffrey R Strawn, John T Walkup","doi":"10.1097/JCP.0000000000002054","DOIUrl":"10.1097/JCP.0000000000002054","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"413-417"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144846660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive Validity of the 5-Factor PANSS Model in Acute Schizophrenia: Early Response to Aripiprazole and Brexpiprazole.","authors":"Yuri Kobayashi, Mizue Ichinose, Toshihiro Terui, Hiroshi Hoshino, Yuhei Suzuki, Sho Horikoshi, Masayuki Goto, Daijiro Yamaguchi, Yoichiro Hirata, Haruka Kaneko, Kenya Watanabe, Keiko Kanno-Nozaki, Satoshi Takeuchi, Itaru Miura","doi":"10.1097/JCP.0000000000002040","DOIUrl":"10.1097/JCP.0000000000002040","url":null,"abstract":"<p><strong>Background: </strong>Predicting early treatment response in acute schizophrenia is critical yet challenging. This observational study aimed to determine whether improvements in specific symptom domains after 2 weeks predict overall response at 6 weeks in patients treated with aripiprazole (ARI) or brexpiprazole (BRE).</p><p><strong>Methods: </strong>We included 65 patients (34 antipsychotic-naïve and 31 antipsychotic-free recurrent) treated with flexible doses of ARI or BRE. Benzodiazepines were used in 41 patients (64.1%), and their use did not significantly impact prediction. The Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression-Improvement were used to assess responses.</p><p><strong>Results: </strong>Receiver operating characteristic analysis revealed area under the curve values for PANSS total (PANSS-T), negative, excitement, cognitive, positive, and depressive/anxiety components of 0.788, 0.783, 0.603, 0.746, 0.738, and 0.735, respectively. Kendall's tau correlation and Cramer's V revealed significant predictive relationships for PANSS-T (0.413, P <0.001), negative (0.411, P <0.001), and therapeutic response dichotomized by this score (0.573, P <0.001), cognitive (0.364, P <0.001), positive (0.344, P <0.001), and depression/anxiety (0.344, P =0.001), but not for excitement (0.15, P =0.151). Benzodiazepine use did not significantly impact these predictive associations.</p><p><strong>Conclusions: </strong>This study is the first to evaluate the predictive validity of the PANSS 5-factor model in patients with acute schizophrenia treated with ARI/BRE. Early symptom improvements, particularly in negative domains, are stronger predictors of overall response, while excitement symptom improvements showed a weaker relationship. These findings underscore the importance of early, symptom-specific assessments to optimize treatment strategies for acute schizophrenia. Further studies with larger samples are necessary to validate these results.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"488-492"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144760175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aripiprazole-Associated Rhabdomyolysis: A Literature Review.","authors":"Jieru Ren, Jing Nie, Lihui Liu, Lei Sun, Ting Wang, Jiyong Wu","doi":"10.1097/JCP.0000000000002031","DOIUrl":"10.1097/JCP.0000000000002031","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"506-508"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144284470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Question: What Is Olfactory Reference Disorder, and How Should We Treat It?","authors":"Katharine A Phillips","doi":"10.1097/JCP.0000000000002050","DOIUrl":"10.1097/JCP.0000000000002050","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"536-538"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144846662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obesity Associated With Symptomatic Remission in Clozapine-Treated Individuals With Treatment-Resistant Schizophrenia.","authors":"Daniel Chang, Yuen Mei See, Jie Yin Yee, Claire Law, Jimmy Lee","doi":"10.1097/JCP.0000000000002048","DOIUrl":"10.1097/JCP.0000000000002048","url":null,"abstract":"<p><strong>Background: </strong>Clozapine, indicated for use in treatment-resistant schizophrenia (TRS), comes with notable weight gain and metabolic side effects. Prior studies have suggested a link between weight gain and antipsychotic efficacy in schizophrenia. In this study, we seek to explore the relationship between obesity and clinical outcome in TRS on clozapine treatment.</p><p><strong>Methods: </strong>This study was conducted at a tertiary mental health institution on patients with TRS on clozapine for at least 12 weeks. Data were collected through a research interview and review of medical records. Symptoms were assessed on the Positive and Negative Syndrome Scale. Anthropometric measures, including weight, height, waist circumference and blood pressure, were measured during the visit. A blood sample for lipids and glucose was obtained after an 8-hour fast.</p><p><strong>Results: </strong>One hundred Fifty-four patients on clozapine were identified and included in the final analysis. Thirty-seven patients (24.0%) achieved symptomatic remission. The remitter group had a significantly higher body mass index (BMI) compared with the nonremitter group (26.6 vs 24.2 kg/m 2 , P = 0.007). Univariate analyses identified BMI, waist circumference and blood pressure as possible metabolic factors associated with remission. In the multivariate model, BMI was the only statistically significant predictor of remission status (OR = 1.147, P = 0.020).</p><p><strong>Conclusions: </strong>Our study found that obesity was associated with remission in TRS patients on clozapine. This lends support to the metabolic threshold for clozapine. Further investigations are needed to study the mechanisms underpinning weight gain and clozapine efficacy.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"484-487"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144821572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of Intramuscular Midazolam, Diphenhydramine, and Haloperidol in Acute Agitation Management in a Psychiatric Emergency Department.","authors":"Andrew M Williams, Rachel Mong, Kuniko Chijiwa, Alaa Alabadi-Bierman, Brandon Q Tran, Phillip Huynh, Teressa Benbarka, Timothy Allison-Aipa","doi":"10.1097/JCP.0000000000002027","DOIUrl":"10.1097/JCP.0000000000002027","url":null,"abstract":"<p><strong>Background: </strong>Intramuscular (IM) lorazepam is administered to acutely agitated patients. During a lorazepam shortage, midazolam was selected as the IM benzodiazepine of choice at this study location. This study aims to explore the efficacy and safety of IM haloperidol, diphenhydramine, and midazolam in treating acutely agitated patients.</p><p><strong>Methods: </strong>A single center, retrospective chart review was conducted in adult patients who received IM diphenhydramine and haloperidol in combination with either midazolam (midazolam+) or lorazepam (lorazepam+) in a psychiatric emergency department (ED) during 2 identified lorazepam shortage periods. Multivariate ordinary least squares and logistic regression analyses were used to evaluate post-IM patients' conditions in behavioral activity rating scale (BARS) scores and the safety and tolerability of IM administrations.</p><p><strong>Results: </strong>A total of 174 patients met inclusion criteria, with 87 patients in the midazolam+ group (treatment) and 87 patients in the lorazepam+ group (control). Lorazepam+ was associated with a 9.4% greater decrease in BARS score than midazolam+ ( P <0.01). Midazolam+ administrations achieved a goal BARS score of 4 more frequently than lorazepam+ ( P <0.05). 18.4% more patients received a BARS score of 2, oversedation with lorazepam+ ( P <0.05). Lorazepam+ patients took nearly 3 hours (176 min) longer than midazolam+ to return to \"normal\" baseline behavior ( P <0.001). No statistically significant differences were detected in the incidence of hypotensive episodes or oxygen desaturation between groups.</p><p><strong>Conclusions: </strong>This is the first study to examine coadministration of intramuscular midazolam with haloperidol and diphenhydramine. Midazolam+ was effective at managing agitation and may be an alternative to lorazepam+.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"471-478"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144266365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sleep-wake Disorders: Systematic Review of Approved Psychiatric Medications (2008 to 2024) and Pipeline Phase-3 Medications.","authors":"Lauren Dugan, Aasim Naqvi, Ashley Ngor, Jayant Totlani, Tiffany Chang, Drew Hirsch, Salma Abdelmoteleb, Thomas Parrish, Piyush Nayyar, Kyla Truman, Michael Irwin, Robert N Pechnick, Itai Danovitch, Waguih W IsHak","doi":"10.1097/JCP.0000000000002049","DOIUrl":"10.1097/JCP.0000000000002049","url":null,"abstract":"<p><strong>Purpose: </strong>This systematic review examines the psychiatric medications approved by the Food and Drug Administration (FDA) for sleep-wake disorders within the past 17 years, from 2008 through 2024, to describe the mechanism of action, indications, evidence for efficacy, dosing, and adverse effects for each medication, as well as the medications that are in the pipeline for approval in phase 3.</p><p><strong>Methods: </strong>Studies published from January 1, 2008, until December 31, 2024, were identified from the PubMed database using the keywords \"sleep*\" AND \"disorder*\" OR \"psychopharm*\" AND \"medic*\" OR \"pharm*.\" An independent, focused analysis was conducted, and a consensus was reached on the studies to be included in this systematic review. Key findings were derived from the full text and tables of the selected studies.</p><p><strong>Results: </strong>From January 1, 2008, to December 31, 2024, the FDA approved 14 medications for sleep-wake disorders and three pipeline medications as of December 31, 2024, currently in phase 3 clinical trials.</p><p><strong>Conclusions: </strong>Through this comprehensive systematic review, stakeholders-including clinicians, researchers, policymakers, and patients-can gain insights into the current treatment landscape and anticipate future therapeutic innovations. This review serves as a resource for guiding treatment decisions and optimizing care for patients with sleep-wake disorders.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"493-505"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144846584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}